How long can life expectancy be extended after taking selinesol tablets?

Selinexor (Selinexor) is an oral drug used to treat certain types of multiple myeloma and other hematologic malignancies. Its mechanism is to inhibit the nuclear export protein XPO1 and promote the accumulation of tumor suppressor factors in tumor cells, thereby exerting anti-tumor effects. There is no fixed answer to the question of extended life expectancy after taking selinesol tablets, because there are many factors that affect a patient's life expectancy, including the patient's basic health condition, stage of the disease, response to treatment, etc.

Clinical trials have shown that selinesol tablets can improve the survival rate of some patients, especially when traditional treatments are ineffective. According to the research data of the SADAL trial, the overall response rate was 28% (95%CI: 20.7-37.0); the complete response rate was 12%, and the partial response rate was 17%. During a median follow-up time of 11.1 months, the median duration of response was 9.3 months (95% CI: 4.8-23.0) for all responders and 23.0 months (95% CI: 10.4-23.0) for CR patients. The median follow-up time was 14.7 months. The median OS was 9.1 months (95% CI: 6.6-15.1). The effectiveness of this drug varies from person to person, and some patients may benefit significantly, while others may have limited effects or major side effects.

While patients are receiving selinesol treatment, they usually need regular blood tests and imaging evaluations to monitor treatment effects and side effects. Common side effects of selinesol include fatigue, nausea, decreased appetite, low platelets, etc. These side effects may affect the patient's quality of life, thereby indirectly affecting survival.

Therefore, while selinesol may provide an increase in survival for some patients, the duration of this increase is affected by multiple factors. Patients should fully communicate with their doctors and make judgments and decisions based on their own circumstances.